Xin 'an medical prevention and treatment of lung distension (chronic obstructive pulmonary disease) clinical research - school capsule treatment of lung distension (chronic obstructive pulmonary disease plateau), lung and kidney deficiency, phlegm and blood stasis resistance pulmonary syndrome patie

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003239

Enrollment

Unknown

Registered

2013-05-23

Start date

2013-06-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

The treatment group:Health education

Contol group:Conventional treatment

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. In line with the diagnostic criteria of COPD patients; 2. Conform to the lung and kidney deficiency, phlegm and blood stasis resistance pulmonary syndromes; 3. Levels of disease degree I, II, III stability of patients; 4. Or the age of 40, 80 years old or less; 5. Rounding out the top one month does not attend other interventions in clinical research; 6. Voluntary treatment, and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with acute aggravating period of COPD; 2. Belong to ? level in patients with COPD stabilization condition level; 3. Pregnancy and nursing mothers; 4. Delirious, dementia, all kinds of mental illness; 5. Cardiac function grade ? and hemodynamic instability; 6. Merger, bronchial asthma, active tuberculosis, bronchiectasis occlusive bronchiolitis, diffuse bronchiolitis, pleural effusion, pulmonary embolism, pneumothorax patients; 7. Neuromuscular diseases affect respiratory movement function; 8. Merger of tumor; 9. Severe kidney disease, severe hepatic disease is refers to liver cirrhosis, portal hypertension and hemorrhage of varices, severe kidney disease including dialysis, kidney transplantation); 10. A variety of reasons in long-term; 11. Rounding out the top 1 months of oral corticosteroids; 12. Congenital or acquired immune deficiency; 13. Taking part in clinical subjects of other drugs, known for treatment of drug allergy.

Design outcomes

Primary

Measure	Time frame
Lung function;Number of COPD exacerbations and degree ;	—

Secondary

Measure	Time frame
Clinical symptoms and signs;TCM syndrome study evaluation;Dyspnea grade;6 minutes walking distance;Quality of life;Drug combination situation;Safety observation index;	—

Countries

China

Contacts

Public ContactLi Zegeng

li6609@126.com+86 13805516609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026